# EDGAR Filing Document

**Accession Number:** 0001023549
**File Stem:** 0001213900-26-019877
**Filing Date:** 2026-2
**Character Count:** 3966
**Document Hash:** 92371c45cd351337929f0e9111207a81
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-019877.hdr.sgml**: 20260224

**ACCESSION NUMBER**: 0001213900-26-019877

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260224

**FILED AS OF DATE**: 20260224

**DATE AS OF CHANGE**: 20260224

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** XTL BIOPHARMACEUTICALS LTD
- **CENTRAL INDEX KEY:** 0001023549
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** L3

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36000
- **FILM NUMBER:** 26671516

**BUSINESS ADDRESS:**
- **STREET 1:** XTL BIOPHARMACEUTICALS LTD
- **STREET 2:** C/O ALSTON & BIRD LLP, 90 PARK AVENUE
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10016
- **BUSINESS PHONE:** 972 9 955 7080

**MAIL ADDRESS:**
- **STREET 1:** 26 BEN-GURION ST.
- **CITY:** RAMAT GAN
- **STATE:** L3
- **ZIP:** 5112001

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form 6-K**

**Report of Foreign Private Issuer**

**Pursuant to Rule 13a-16 or 15d-16**

**of the Securities Exchange Act of 1934**

For the month of February 2026

Commission File Number: 001-36000

**XTL Biopharmaceuticals Ltd.** 

(Exact name of Registrant as specified in its charter)

**85 Medinat ha-Yehudim St.**

**Herzliya,<br> 4676670, Israel**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

On January 13, 2026, XTL Biopharmaceuticals Ltd. (the "**Company**") announced that it will hold Extraordinary General Meeting of Shareholders (the "**Meeting**") on February 17, 2026, at the offices of the Company's attorneys, Amit, Pollak, Matalon & Co., at APM House, 18 Raoul Wallenberg St., Building D, 6th floor, Ramat Hachayal, Tel Aviv, Israel at 04:00 PM (Israel Time). However, on February 17, 2026, the Meeting was adjourned for one week to the same day, time and place due to lack of quorum.

The Company announces today, the results of the Meeting, held today, Tuesday, February 24, 2026, in Tel Aviv, Israel. At the Meeting, all of the proposals set forth in Company's announcement dated January 13, 2026, were approved by the required majority of the shareholders. The resolutions were as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. To approve an increase
of the Company's authorized share capital by 1,450,000,000 shares, such that following the increase, the authorized share capital
will consist of a total of 2,900,000,000 ordinary shares, par value NIS 0.1 each, and to amend the Company's Articles of Association
accordingly; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. To re-elect Ms. Iris Shapira Yalon to hold office, for an additional
term, as an external director of the Company, effective as of January 29, 2026, for a period of three (3) years, until January 29, 2029;
and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. To approve, for purposes including but not limited to compliance
with Nasdaq Rule §5635(c), the issuance and sale in a private placement of securities in the aggregate amount of up to US$2,000,000
to certain investors, including officers and directors of the Company and an Interested Party, such funding to be contingent upon the
consummation of the transaction relating to NeuroNOS Ltd., as further described in the Company's Form 6-K filed on January 13, 2026

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
|  | **XTL Biopharmaceuticals Ltd.** |
| Date: February 24, 2026 | */s/* Noam Band |
|  | Noam Band |
|  | Chief Executive Officer |

---